Dr. Michael Chopp Reports on Successful Remodeling of the Central and Peripheral Nervous Systems after Injury/Disease Using Thymosin Beta 4
PR Newswire

ROCKVILLE, Md., Oct. 23, 2014 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today reported on data presented by Dr. Michael Chopp at the Fourth International Symposium on Thymosins in Health and Disease in Rome, Italy.  Dr. Chopp reviewed research on the use of Thymosin beta 4 (TB4) as a protective and regenerative agent for nervous system injuries and diseases.  He also presented data on the molecular mechanisms underlying TB4's therapeutic efficacy, including its modulation of microRNAs and their subsequent multifaceted restorative impact.

"A plethora of neuroprotective agents, primarily for injury/disease of the central nervous system (CNS), such as stroke, traumatic brain injury (TBI) and multiple sclerosis (MS), have not shown clinical efficacy.  A different approach aimed at endogenous tissue protection and enhancing tissue regeneration may be more beneficial and lead to significant improvement and possibly restoration of neurological function post-neural injury/disease," according to Michael Chopp, Ph.D., scientific director of the Henry Ford Neuroscience Institute, and the Zoltan J. Kovacs Chair in Neuroscience Research. "TB4 appears to provide remarkably similar and consistent neurorestorative therapeutic benefits over a broad range of neurological pathologies, resulting in neurovascular remodeling and tissue regeneration and, thereby, functional recovery in our animal models," he concluded.

"Similar reports have been published by research teams in the U.S., Great Britain, and Germany in cardiovascular models showing accelerated repair and remodeling of cardiovascular tissue and functional improvement in cardiac output after systemic administration of TB4.  It is exciting that Dr. Chopp and his colleagues have shown equally impressive results in CNS and PNS models," stated Dr. Allan Goldstein, co-chair of the Thymosin Symposium, Emeritus Chair of the Department of Biochemistry and Molecular Biology at the George Washington University, Washington, DC, and scientific advisor to RegeneRx Biopharmaceuticals, Inc.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac, CNS and dermal indications, strategic licensing agreements in China, the EU, and in other Pan Asia countries, including Korea, Japan and Australia, and has an extensive worldwide patent portfolio covering its products.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning research and clinical development and future commercialization of the Company's drug candidates, the design and length of clinical trials, and other regulatory interaction.  Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can also be no assurance that any clinical trial undertaken by RegeneRx or its licensees will be commercially successful or that the FDA or other government agency will not have additional comments, restrictions, or guidance revisions regarding future clinical development or drug applications. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE RegeneRx Biopharmaceuticals, Inc.